Th1/Th2 cells in inflammatory disease states: Therapeutic implications

Expert Opinion on Biological Therapy

Volumn 4, Issue 12, 2004, Pages 1887-1896

  Moss, Ronald B ^a   Moll, Thomas ^a   El Kalay, Mohammad ^a   Kohne, Connie ^a   Hoo, William Soo ^a   Encinas, Jeffrey ^a   Carlo, Dennis J ^a  

^a Telos Pharmaceuticals LLC   (United States)

Author keywords

Allergy; Autoimmunity; Cancer; CpG; Heat shock proteins; Infectious disease; Inflammation; T cell immunoglobulin mucin domain; T helper; TIM 1; TIM 3

Indexed keywords

AUTACOID; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 2; INTERLEUKIN 4; TUMOR NECROSIS FACTOR ALPHA;

ALLERGY; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CANCER; CELLULAR IMMUNITY; CYTOKINE RELEASE; DIABETES MELLITUS; HEART DISEASE; HELPER CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOREGULATION; INFECTION; INFLAMMATION; INFLAMMATORY DISEASE; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE FUNCTION; LYMPHOCYTIC INFILTRATION; MONONUCLEAR CELL; MULTIPLE SCLEROSIS; NONHUMAN; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; TECHNIQUE; TH1 CELL; TH2 CELL;

ANIMALS; ANTI-INFLAMMATORY AGENTS; AUTOIMMUNE DISEASES; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; INFLAMMATION; TH1 CELLS; TH2 CELLS;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 10344220475     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.4.12.1887     Document Type: Review

References (76)

1. GALLIN JL, GOLDSTEIN IM, SNYDERMAN R: Inflammation: Basic Principles and Clinical Correlates. Gallin JL, Goldstein IM, Snyderman R (Eds), Raven Press, New York, USA (1988).
2. CHERWINSK HM, SCHUMACHER JH, BROWN KD, MOSMANN TR: Two types of mouse helper T cell done. III. Further differences in lymphocyte synthesis between Th1 and Th2 clones revealed by RNA hybridization, functionally mono-specific bioassays, and monoclonal antibodies. J. Exp. Med. (1987) 166:1229-1244.
3. ROMAGNANI S: Human Th1 and Th2 subsets: doubts no more, Immunol. Today (1991) 12:256-257.
4. KAPSENBERG M: Dendritic cell control of pathogen driven T cell polarization. Nat. Rev. Immunol. (2003) 3:984-993.
5. BARTON GM, MEDZHITOV R: Toll-like recepror signaling pathways. Science (2003) 300:1524-1525.
6. EISENBARTH SC, PIGGOTT DA, HULEATT JW, VISINTIN I, HERRICK CA, BOTTOMLY K: Lipolysaccaride-enhanced, Toll like receptor 4 dependent T helper cell Type 2 responses to inhaled antigen. J. Exp. Med. (2002) 197:101-109.
7. REDECKE V, HACKER H, DATTA SK et al.: Activation of toll like receptor 2 induces a Th2 immune response and promotes experimental asthma. J. Immunol (2004) 172:2739-2743.
8. ROMAGNANI S: The increased prevalence of allergy and the hygiene hypothesis: missing immune deviation, reduced immune suppression or both? Immunology (2004) 112:352-362.
9. NO AUTHORS LISTED: National Asthma Education And Prevention Export Panel Report. National Heart, Lung, And Blood Institute, USA (1997).
10. ROBINSON DS, HAMID Q, YING S et al.: Predominant TH2-like bronchoalveolar T lymphocyte population in atopic asthma. N. Engl. J. Med. (1992) 326:298-304.
11. CORRIGAN CJ, HACZKU A, GEMOU-ENGESAETH V et al: CD4 T lymphocyte activation in asthma is accompanied by increased serum concentrations of Interluekin-5, effects of glucocorticoid therapy. Am. Rev. Respir. Dis. (1993) 147:540-547.
12. KAY AB: Allergy and allergic disease. N. Engl. J. Med. (2001) 344:30-37.
13. HERRICK C, BOTTOMLY K: To respond or not respond: T cells in allergic asthma. Nat. Rev. Immunol. (2003) 3:405-412.
14. FINOTTO S, NEURATH MF, GLICKMAN JN et al.: Development of spontaneous airway changes consistent with human asthma in lice lacking T-bet. Science (2002) 295:336-338.
15. CORRIGAN CJ, KAY AB: CD4 T lymphocyte activation in acute severe asthma. Relationship to disease severity and atopic status. Am. Rev. Respir. Dis. (1990) 141:970-977.
16. MOSS RB, SCOTT TA, GOLDRICH M et al.: Nasal mucosal cells in human immunodeficiency virus type 1-seropositive patients with sinusitis. J. Clin. Lab. Anal. (1996) 10:18-22.
17. CLERICI M, GIORGI JV, CHOU CC et al.: Cell mediated immune response to human immunodeficiency virus type 1 in seronegative homosexual men with recent sexual exposure to HIV-1. J. Infect. Dis. (1992) 165:1012-1019.
18. ROMAGNANI S: Regulation of the development of type 2 T-helper cells in allergy. Curr. Opin. Immunol. (1994) 6:616-622.
19. MAGGI E, MAZZETTI M, RAVINA A et al.: Ability of HIV-1 to promote a Th1 to Th0 shift and to replicate preferentially in Th2 and Th0 cells. Science (1994) 265:244-244.
20. FOWKE KR, NAGELKERKE NJ, KIMANI J et al.: Resistance to HIV-1 infection among persistently seronegative prostitutes in Nairobi, Kenya. Lancet (1996) 348:1347-1351.
21. ROWLAND-JONES SL, DONG T, FOWKE KR et al: Cytotoxic T cell responses to multiple conserved HIV epitopes in HIV resistant prostitutes in Nairobi. J. Clin. Invest. (1998) 102:1758-1765.
22. MOSS RB, SALK P: CD8+ memory T cells require CD4+ T cell help: implications for therapeutic and preventative HIV vaccines. AIDSCIENCE (2003):3.
23. SALK P, SALK J: Cell mediated immunologic memory in prevention of and treatment of HIV disease. Res. Immunol. (1994) 145:629-633.
24. CHOY E, PANAYI GS: Cytokine pathways and joint inflammation in rheumatoid arthritis. N. Engl. J. Med. (2001) 344:907-916.
25. VAN DE PUTTE LB, RAU R, BREEDVELD FC et al.: Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week Phase II study. Ann. Rheum. Dis. (2003) 62:1168-1177.
26. RUDDICK RA, COHEN JA, WEINSTOCK-GUTTMAN B, KIMKEL RP, RANSOHOFF RM: Management of multiple sclerosis. N. Engl. J. Med. (1997) 337:1604-1611.
27. TRAUGOT U, REINHERZ EL, RAINE CS: Multiple sclerosis: distribution of T cells, T cell subsets, and I-a positive macrophages in lesions of different ages. J. Neuroimmunol. (1983) 4:201-221.
28. NATHAN D: Long-term complications of diabetes. N. Engl. J. Med. (1993) 328:1676-1685.
29. BOTTAZZO GF, DEAN BM, MCNALLY JM, MACKAY EH, SWIFT PG, GAMBLE DR: In situ characterization of autoimmune phenomena and expression of HLA molecules in the pancreas in diabetic insulitis. N. Engl. J. Med. (1985) 313:353-360.
30. REBINOVITCH A, SUEREZ-PINZON WL: Cytokines and their roles in pancreatic islet beta cell destruction and insulin dependent diabetes mellitus. Biochem. Phamacol. (1998) 11:39-49.
31. HEROLD KC, HAGOPIAN W, AUGER JA et al.: Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N. Engl. J. Med. (2002) 346:1692-1698.
32. ROSS R: Atherosclerosis - an inflammatory disease. N. Engl J. Med. (1999) 340:115-126.
33. KIECHL S, WIEDERMANN CJ, WILLEIT J: Toll-like receptor 4 and atherogenesis. Ann. Med. (2003) 35:164-171.
34. DE KLEIJN D, PASTERKAMP G: Toll-like receptors in cardiovascular diseases. Cardiovasc. Res. (2003) 15:58-67.
35. RIDKER PH, HENNEKENS CH, BURING JE, RIFAI N: C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N. Engl. J. Med. (2000) 342:836-843.
36. DUDLEY ME, ROSENBERG SA: Adoptive cell transfer therapy for the treatment of patients with cancer. Nature (2003) 3:666-674.
37. NISHIMURA T, IWAKABE K, SEKIMOTO M et al.: Distinct role of antigen-specific T helper type 1 (Th1) and Th2 cells in tumor eradication in vivo. J. Exp. Med. (1999) 5:617-627.
38. KOUTSKY LA, AULT KA, WHEELER CM et al.: A controlled trial of a human papillomavirus type 16 vaccine. N. Engl. J. Med. (2002) 21:1645-1651.
39. PINTO LA, EDWARDS J, CASTLE PE et al.: Cellular immune responses to human papillomavirus (HPV)-16 L1 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles. J. Infect. Dis. (2003) 188:327-338.
40. SALK JE: Studies in human subjects on active immunization against poliomyelitis. JAMA (1953) 151:1081-1098.
41. HILLEMAN MR: Overview of the needs and realities for developing new and improved vaccines in the 21st Century. Intervirilogy (2002) 45:199-211.
42. BENTWICH Z, WEISMAN Z, MOROZ C, BAR-YEHUDA S, KALINKOVICH A: Immune dysregulation in Ethiopian immigrants in Israel, relevance to helminth infections? Clin. Exp. Immunol. (1996) 103:239-243.
43. BENTWICH Z, KALINKOVICH A, WEISMAN Z: Immune activation is a dominant factor in the pathogenesis of African AIDS. ImmunoL Today (1995) 16:187-191.
44. WOLDAY D, MAYAAN S, MARIAM ZG et al: Treatment of intestinal worms is associated with decreased HIV plasma viral load. J. Acquir. Immune Defic. Syndr. (2002) 31:56-62.
45. WILLIAMS CF, KLINZMAN D, YAMASHITA T et al.: Persistent GB virus C infection and survival in HIV-infected men. N. Engl. J. Med. (2004) 350:981-990.
46. NUNNARI G, NIGRO L, PALERMO F et al.: Slower progression of HIV-1 Infection in persons with GB virus C co-infection correlates with an intact T helper cytokine profile. Ann. Intern. Med. (2003) 139:26-30.
47. XIANG J, GEORGE S, WUNSCHMAN S, CHUG Q, KLINZMAN D, STAPLETON J: Inhibition of replication by GB virus C infection through increase in Rantes, MIP-1α, MIP-1β, and SDF-1. Lancet (2004) 363:2040-2046.
48. YAZDANBAKHSH M, MATRICARDI PM: Parasites and the hygiene hypothesis; regulating the immune system? Clin. Rev. Allergy Immunol. (2004) 1:15-24.
49. WILLIAMS LK, PETERSON EL, OWNBY DR, JOHNSON CC: The relationship between carry fever and allergic sensitization at age 6 to 7 years. J. Allergy Clin. Immunol. (2004) 113:291-296.
50. TAMURA Y, PENG P, LUI K, DAOU M, SRIVASTAVA PK: Immunotherapy of tumors with autologous tumor derived heat shock proteins preparations. Science (1997) 27:117-120.
51. WAN T, ZHOU X, CHEN G et al.: Novel heat shock protein HSP70L1 activates dentritic cells and acts as a Th1 polarizing adjuvant. Blood (2004) 103:1747-1754.
52. HOOS A, LEVEY DL: Vaccination with heat shock protein-peptide complexes: from basic science to clinical applications. Expert Rev. Vaccines (2003) 3:369-379.
53. TOKUNAGA T, YAMAMOTO H, SHIMADA S et al.: Antitumor activity of deoxyribunucleic acid fraction from Mycobacterium bovis BCG. I. Isolation, physicochemical characterization, and and tumor activity. J. Natl. Cancer Inst. (1984) 72:955-962.
54. MOHAMADAZDEH M, LUFTIG R: Dendritic cells: in the forefront of immunopathogenesis and vaccine development - a review. J. Immune Based Ther. Vaccines (2004) 2:1.
55. DUMAIS N, PATRICK A, MOSS RB, DAVIS HL, ROSENTHAL KL: Mucosal immunization with inactivated human immunodeficiency virus plus CpG oligodeoxynucleeotides induce genital immune responses and protection against intravaginal challenge. J. Infect. Dis. (2002) 186:1098-1105.
56. GOLDBERG B, URNOVIT HB, STRICKER RB: Beyond Danger: unmethylated CpG dinudeotides and the immunopathogenesis of disease. Immunol. Lett. (2000) 73:13-18.
57. SEGAL BM, CHANG JT, SHEVACH EM: CpG oligonucleotides are potent adjuvants for the activation of autoreactive encephalitogenic T cells in vivo. J. Immunol. (2000) 164:5683-5688.
58. KRIEG AM: The role of CpG motifs in innate immunity. Curr. Opin. Immunol. (2000) 12:35-43.
59. KLINE JN, WALDSCHMIDT TJ, BUSINGA TR et al.: Modulation of airway inflammation by CpG oligonucleotides in a murine model of asthma. J. Immunol. (1998) 160:2555-2559.
60. CHIANG DJ, YE YL, CHEN WL, LEE YL, HSU NY, CHIANG BL: Ribavarin or CpG DNA sequence-modulated dendritic cells decrease the IgE level and airway inflammation. Am. J. Respir. Crit. Care Med. (2003) 68:575-580.
61. SHIROTA H, SANO K, KIKUCHI T, TAMURA G, SHIRATO K: Regulation of T-helper type 2 cell and airway eosinophilia by transmucosal coadminsitration of antigen and oligodeoxynucleotides containing CpG motifs. Am. J. Respir. Cell Mol. Biol. (2000) 22:176-182.
62. MOSS RB, DIVELEY J, JENSEN F, CARLO DJ: In vitro immune function after vaccination with an inactivated, gp 120-depleted HIV-1 antigen with immunostimulatory oligodeoxynucleotides. Vaccine (2000) 18:1081-1087.
63. HORNER AA, RAZE: Immunostimulatoty sequence oligodeoxynucleotides: a novel mucosal adjuvant. Clin. Immmunol. (2000) 95:S19-S29.
64. CORRAL RS, PETRAY PB: CpG DNA as a Th1-promoting adjuvant in immunization against Trypanosoma cruzi. Vaccine (2000) 19:234-242.
65. HEIKENWALDER M, POLYMENIDOU M, JUNT T et al.: Lymphoid follicle destruction and immunsuppression after repeated CpG oligodeoxynucleotide administration. Nat. Med. (2004) 2:187-192.
66. MCINTIRE JJ, UMETSU SE, AKBARI O et al.: Identification of Tapr (an airway hyperreactivity regulatory locus) and the linked Tim gene family. Nat. Immunol. (2001) 2:1109-1116.
67. MONNEY L, SABATOS CA, GAGLIA JL et al.: Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature (2002) 415:536-541.
68. ICHIMURA T, BONVENTRE JV, BAILLY V et al.: Kidney injury molecule-1 (KIM-1), a putative epithelial cell adhesion molecule containing a novel immunoglobulin domain, is up-regulated in renal cells after injury. J. Biol. Chem. (1998) 273:4135-4142.
69. KAPLAN G, TOTSUKA A, THOMPSON P, AKATSUKA A, MORITSUGU Y, FEINSTON SM: Identification of a surface glycoprotein on African green monkey kidney cells as a receptor for hepatitis A virus. EMBO J. (1996) 15:4282-4296.
70. KUCHROO VK, UMETSU DT, DEKRUYFF RH, FREEMAN GJ: The TIM gene family: emerging roles in immunity and disease. Nat. Rev. Immunol. (2003) 3:454-462.
71. MATRICARDI PM, ROSMINI F, FERRIGNO L et al.: Cross sectional retrospective study of prevalence of atopy among Italian military students with antibodies against hepatitis A virus. Br. Med. J. (1997) 314:999-1003.
72. MATRICARDI PM, ROSMINI F, PANETTA V, FERRIGNO L, BONINI S: Hay fever and asthma in relation to markers of infection in the United States. J. Allergy Clin. Immunol. (2002) 110:381-387.
73. MCINTIRE JJ, UMETSU SE, MACAUBAS C et al.: Immunology: hepatitis A virus link to atopic disease. Nature (2003) 425:576.
74. CHAE SC, SONG JH, LEE YC, KIM JW, CHUNG HT: The association of the exon 4 variations of Tim-1 gene with allergic diseases in a Korean population. Biocbem. Biophys. Res. Commun. (2003) 312:346-350.
75. SANCHEZ-FUEYO A, TIAN J, PICARELLA D et al: Tim-3 inhibits T helper type 1-mediated auto- and alloimmune responses and promotes immunological tolerance. Nat. Immunol. (2003) 4:1093-1101.
76. SABATOS CA, CHAKRAVARTI S, CHA E et al.: Interaction of Tim-3 and Tim-3 ligand regulates T helper type 1 responses and induction of peripheral tolerance, Nat. Immunol. (2003) 4:1102-1110.